Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited has appointed Richard Jarvis of The CFO Bridge as interim Chief Financial Officer, effective immediately, while it undertakes an executive search with Stanton Chase for a permanent CFO to lead the finance function through its next growth phase. The move is part of a broader effort to strengthen the leadership team as Artrya progresses the commercialisation of its Salix AI platform and expands its presence in the U.S. market, with management emphasising the need for seasoned executives who can support scaling the business, drive commercial outcomes and underpin the company’s growth strategy.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited (ASX: AYA) is an Australian medical technology company focused on AI-powered solutions for the detection and management of coronary artery disease. Its proprietary Salix cloud platform analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians with near real-time, point-of-care assessment and more accurate, efficient diagnosis. The company is pursuing regulatory and commercial pathways in key international markets as it seeks to advance cardiac care through innovative technology.
Average Trading Volume: 839,130
Technical Sentiment Signal: Buy
Current Market Cap: A$667.1M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.